Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
UBS Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
June 20, 2024 6:10 AM EDTUBS analyst Eliana Merle downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Buy to Neutral with a price target of $5.00 (from $28.00).
The analyst comments "We think WEE1 has potential in ovarian and USC, but we see uncertainty and have limited visibility on next steps given partial clinical hold announced 6/18 A partial clinical hold was placed by the FDA on azenosertib (WEE1... More
Jefferies Downgrades Zentalis Pharmaceuticals (ZNTL) to Hold
June 18, 2024 2:19 PM EDTJefferies analyst Akash Tewari downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Buy to Hold with a price target of $6.00 (from $42.00).
The analyst comments "ZNTL announced the FDA placed a partial clinical hold on 3 mono azenosertib studies after 2 deaths presumably due to sepsis (neutropenia &... More
Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight
June 18, 2024 1:32 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Overweight to Equalweight with a price target of $8.00 (from $38.00).
The analyst comments "Lead program azenosertib placed on partial clinical hold by the FDA due to safety concerns. While we continue to believe... More
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $20 at H.C. Wainwright
June 18, 2024 12:13 PM EDTH.C. Wainwright analyst Andrew Fein lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $20.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "Azenosertibs clinical hold is based on toxicity issues well known to WEE1i. This morning, Zentalis announced that the FDA has placed three clinical studies of azenosertib (ZN-c3-001, ZN-c3-004/TETON, and ZN-c3-005/DENALI) on partial hold following two drug-related Grade 5 events... More
